Chase Therapeutics

Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on developing better treatments for brain disorders. The company concentrates on rapidly translating therapeutic breakthroughs in neuroscience research that may help prevent and potentially cure central nervous system dysfunction. Its leading pipeline drugs include CTC-413 for palliative and neuroprotective treatment of Parkinson's disease and CTC-501 for major depressive disorder. Both drugs, along with a companion diagnostic for Parkinson's disease, have now entered the third phase of development. Chase Therapeutics is committed to improving the lives of all those suffering from neuropsychiatric disorders.